Data-driven multiscale modeling deciphers MOI-dependent dual antiviral mechanisms of OP7
- 1Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany
Abstract
OP7 defective interfering particles are promising antivirals against influenza A virus (IAV), but their antiviral mechanisms are not fully understood. Here, we developed a data-driven multiscale model of IAV and OP7 coinfection calibrated to in vitro human lung cell data. The model predicted, and experiments confirmed, a previously unrecognized multiplicity of infection (MOI)-dependent switch in the relative contribution of two complementary antiviral mechanisms of OP7. For low IAV MOI, OP7-mediated interferon signaling induces the antiviral effector MxA, restricting nuclear import of IAV genomes, while replication interference subsequently reinforces complete suppression of virus replication. For high MOI coinfection, the interferon response established is too slow to contribute to antiviral activity, and virus inhibition is mediated almost exclusively by replication interference. The model further predicted a therapeutic efficacy of OP7 up to 24 h post infection, which was confirmed in subsequent experiments. Following extension, it also reproduced the experimentally defined prophylactic protection for up to 7 days. Altogether, this experimentally validated coinfection model provides a quantitative framework for understanding and rationally optimizing prospective OP7-based antiviral therapies.
Related
- Integrated multi-omics analysis deciphers the molecular mechanisms underlying the characteristic volatile flavor of Meishan pork
- Modeling of the human rhinovirus C capsid suggests possible causes for antiviral drug resistance
- Fetal-intrinsic antiviral mechanisms emerge over the course of gestation
- The COX2-PGE2-PKA axis suppresses antiviral immunity by inhibiting mtDNA-dependent STING activation
- Antiviral Action Mechanisms of a Synthetic GM-CSF Active-Center Peptide.
BibTeX
@misc{ruediger2026datadriven,
title = {{Data-driven multiscale modeling deciphers MOI-dependent dual antiviral mechanisms of OP7}},
author = {D. Ruediger and P. Opitz and J. Kuechler and U. Reichl and S. Y. Kupke},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.08.750025},
url = {https://www.biorxiv.org/content/10.64898/2026.09.08.750025v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Data-driven multiscale modeling deciphers MOI-dependent dual antiviral mechanisms of OP7
AU - D. Ruediger
AU - P. Opitz
AU - J. Kuechler
AU - U. Reichl
AU - S. Y. Kupke
PY - 2026
DA - 2026/09/08
PB - bioRxiv
DO - 10.64898/2026.09.08.750025
UR - https://www.biorxiv.org/content/10.64898/2026.09.08.750025v1
AB - OP7 defective interfering particles are promising antivirals against influenza A virus (IAV), but their antiviral mechanisms are not fully understood. Here, we developed a data-driven multiscale model of IAV and OP7 coinfection calibrated to in vitro human lung cell data. The model predicted, and experiments confirmed, a previously unrecognized multiplicity of infection (MOI)-dependent switch in the relative contribution of two complementary antiviral mechanisms of OP7. For low IAV MOI, OP7-mediated interferon signaling induces the antiviral effector MxA, restricting nuclear import of IAV genomes, while replication interference subsequently reinforces complete suppression of virus replication. For high MOI coinfection, the interferon response established is too slow to contribute to antiviral activity, and virus inhibition is mediated almost exclusively by replication interference. The model further predicted a therapeutic efficacy of OP7 up to 24 h post infection, which was confirmed in subsequent experiments. Following extension, it also reproduced the experimentally defined prophylactic protection for up to 7 days. Altogether, this experimentally validated coinfection model provides a quantitative framework for understanding and rationally optimizing prospective OP7-based antiviral therapies.
ER -